NCT02296918 2025-12-19Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLAcerta Pharma BVPhase 1 Completed69 enrolled
NCT02007044 2025-11-06Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaM.D. Anderson Cancer CenterPhase 2 Active not recruiting66 enrolled